Proparacaine hydrochloride eye drops and production process thereof
By circulating multi-layer filtration and adjusting ingredients, the contamination and insufficient components of propmecaine hydrochloride eye drops were solved, and the preparation of eye drops without antibacterial agents was achieved, which improved safety and use effect.
Patent Information
- Application Number
- CN202410470411.0
- Authority / Receiving Office
- CN · China
- Patent Type
- Patents(China)
- Current Assignee / Owner
- Filing Date
- 2024-04-18
- Publication Date
- 2024-12-03
- Estimated Expiration
- 2044-04-18
AI Technical Summary
The existing propmecaine hydrochloride eye drops are easily contaminated by tears and microorganisms in the air during use and storage, resulting in the need to add antibacterial agents, which are harmful to eye tissues; single-dose packaging is small due to the small amount of components. It is difficult to ensure that the viscosity and osmotic pressure of eye drops are within the optimal range, which affects the use effect.
Single dose eye drops are made using propmecaine hydrochloride and auxiliary materials. Through circulating multi-layer filtration technology, avoid the use of antibacterial agents, and adjust the addition ratio of glycerol and propmecaine hydrochloride, combined with the pH adjustment of dilute hydrochloric acid. , ensure that the osmotic pressure and viscosity of the eye drops are within the optimal range.
Effectively reduces the irritation and damage to eye tissue by eye drops, improves the safety and comfort of medication, ensures the sterility and quality of eye drops, avoids the adverse effects caused by antibacterial agents, and has viscosity and osmotic pressure. Within the optimal use range of patients.
Smart Images

Figure BDA0004798739490000061 
Figure BDA0004798739490000071 
Figure BDA0004798739490000081
Abstract
Description
Technical Field
[0001] The invention belongs to the technical field of medicines, and in particular relates to proparacaine hydrochloride eye drops and a production process thereof. Background Art
[0002] Proparacaine hydrochloride eye drops are indicated for ophthalmic surface anesthesia, such as: tonometer measurement of intraocular pressure, surgical suture and foreign body removal, conjunctival and corneal scraping, anterior chamber corneal examination, three-mirror examination and other operations requiring surface anesthesia.
[0003] At present, most of the proparacaine hydrochloride eye drops commonly used in ophthalmology are multi-dose packages, which are large in size and have a long use time. During use and storage, they are easily contaminated by microorganisms in tears and air. Therefore, multi-dose eye drops generally add one or more antibacterial agents to prevent secondary contamination during use. However, antibacterial agents have certain damage to eye tissues. It is reported that a high concentration of antibacterial agents can cause damage to the corneal epithelium after a single eye drop; even if the concentration of antibacterial agents in eye drops is low, long-term use can cause corneal damage, and even lead to corneal endothelial damage or eye allergic reactions. Single-dose packaged eye drops have a small volume, are mostly used once or for a short time, do not cause secondary contamination, and do not require the addition of antibacterial agents. They have become one of the current research directions for ophthalmic preparations.
[0004] However, in the process of producing single-dose proparacaine hydrochloride eye drops, since fewer components need to be added, while ensuring that the amounts of the main ingredient (proparacaine hydrochloride) and auxiliary materials (thickeners) meet the standards, the viscosity and osmotic pressure of the produced eye drops cannot be guaranteed to be within the optimal use range, resulting in poor use effect of the eye drops. Summary of the invention
[0005] In view of the problems existing in the current proparacaine hydrochloride eye drops production process mentioned above, the present invention provides a proparacaine hydrochloride eye drops and a production process thereof, wherein a single-dose eye drops is prepared using proparacaine hydrochloride and auxiliary materials as materials, and a circulating multi-layer filtration technology is used. Compared with the existing proparacaine hydrochloride eye drops production process, no antibacterial agent is required, and the osmotic pressure and viscosity of the eye drops are ensured to be within the optimal range for patients. The specific technical scheme is as follows:
[0006] First, the present invention provides a production process of proparacaine hydrochloride eye drops, comprising the following steps:
[0007] S1: Prepare liquid: take 30% to 40% of the total volume of water for injection, add glycerol, stir to dissolve, add proparacaine hydrochloride, stir until completely dissolved, adjust the pH value with dilute hydrochloric acid, inject the remaining water for injection, stir and mix evenly to prepare liquid medicine;
[0008] S2 filtration: The drug solution is transported to the first filter for cyclic filtration. After the cyclic filtration, the drug solution is filtered through the second filter and the third filter in sequence. After the filtration, the drug solution is stored in a buffer tank;
[0009] S3 filling: discharge the liquid medicine to flush the filling pipeline, adjust the filling machine parameters to convey the liquid medicine for filling, and take out the filled medicine bottles at intervals during the filling process to measure, check and record;
[0010] S4 Inspection: Inspect the filled medicine bottles one by one, and package and store them after passing the inspection.
[0011] Furthermore, in step S1, the temperature of the water for injection for preparing proparacaine hydrochloride is 45-60° C., and the pH value of the liquid medicine is 5-5.7.
[0012] Furthermore, the concentration of dilute hydrochloric acid in step S1 is 0.1 mol / L.
[0013] Furthermore, in step S2, the filter element size of the first filter is 0.45 μm, and the circulation filtration time is 10 to 15 minutes; the filter element size of the second filter is 0.45 μm; and the filter element size of the third filter is 0.22 μm.
[0014] Furthermore, in step S3, the number of times the medicinal liquid is discharged and flushed is 140 to 200 times; and the single filling weight is 0.430 g to 0.490 g.
[0015] Furthermore, in step S3, a filter element integrity test is required before the filling machine is used, and the filter element includes a supporting air filter element, a buffer tank compressed air filter element and an A-level air shower device filter element; the pore size of the supporting air filter element and the buffer tank compressed air filter element is 0.22 μm, and the pore size of the A-level air shower device filter element is 0.2 μm.
[0016] Furthermore, the filling machine filter element integrity test parameters in step S3 include minimum bubble point, water intrusion test pressure value, maximum flow value and diffusion flow test pressure; the minimum bubble point of the support gas filtration is 1000mbar, the water intrusion test pressure value is 2500mbar, and the maximum flow value is 0.75ml / min; the minimum bubble point of the buffer tank compressed air filtration is 1100mbar, the water intrusion test pressure value is 2500mbar, the maximum flow value is 0.38ml / min, and the diffusion flow test pressure is 80Kpa; the minimum bubble point of the buffer tank compressed air filtration is 11100mbar, the water intrusion test pressure value is 2600mbar, the maximum flow value is 0.75ml / min, and the diffusion flow test pressure is 970mbaar.
[0017] Furthermore, in step S3, the filling machine needs to be sterilized before use, and the sterilization temperature is 121° C. to 135° C. and the time is 20 to 30 minutes.
[0018] The invention also discloses a proparacaine hydrochloride eye drop, which is composed of the following parts by weight: 0.5% to 1% proparacaine hydrochloride, 3.5% to 4% glycerol, 0.001% to 0.005% hydrochloric acid, and the rest is water for injection.
[0019] Furthermore, the osmotic pressure ratio of the proparacaine hydrochloride eye drops is 0.93-1.07; and the viscosity is 3.7-4.2 mPa·s.
[0020] Compared with the prior art, the proparacaine hydrochloride eye drops of the present invention have the following beneficial effects:
[0021] 1) The proparacaine hydrochloride eye drops prepared by the present invention do not contain preservatives. Preparing the proparacaine hydrochloride eye drops into single-dose eye drops can effectively reduce the stimulation and damage of the drug solution to eye tissues, avoid the adverse effects of antibacterial agents or other components contained in existing eye drops, and improve the safety and comfort of medication for patients.
[0022] 2) In the proparacaine hydrochloride eye drops prepared by the present invention, the addition ratio of glycerol to proparacaine hydrochloride is controlled, and the viscosity of the prepared eye drops is ensured to be 3.7-4.2 mPa·s, and the osmotic pressure ratio is 0.93-1.07 through multiple cycle filtration technology and three-in-one filling. The pH value is adjusted to be 5-5.7 by adding hydrochloric acid of a specific concentration, thereby ensuring that the eye drops are in the most suitable use range for patients, improving the comfort of consumers and not causing irritation and damage to the patient's eye mucosa.
[0023] 3) The present invention uses a circulating filtration scheme in the initial filtration stage of the filtration operation, which can ensure that the prepared liquid medicine is fully circulated and filtered in the first filter, effectively reducing the microbial content in the eye drops and improving the sterility assurance level of the eye drops. At the same time, combined with the random inspection after the circulating filtration, the quality problems in the eye drops production process can be discovered and fed back in time, improving the safety and rationality of production. DETAILED DESCRIPTION
[0024] In order to make the purpose, technical solution and advantages of the present invention more clear, the technical solution of the present invention will be clearly and completely described below in conjunction with embodiments.
[0025] Example 1
[0026] This embodiment provides a production process of proparacaine hydrochloride eye drops, which specifically includes the following steps:
[0027] S1: Prepare liquid: take 30% to 40% of the total volume of water for injection, add glycerol, stir to dissolve, add proparacaine hydrochloride, stir until completely dissolved, adjust the pH value with dilute hydrochloric acid, inject the remaining water for injection, stir and mix evenly to prepare liquid medicine;
[0028] Specifically, first weigh the corresponding mass fractions of proparacaine hydrochloride and thickener, and in this embodiment, the thickener is glycerol. In this embodiment, 150,000 metering portions are weighed, wherein 300g of proparacaine hydrochloride and 2335g of glycerol are weighed. Subsequently, a clean stainless steel barrel is used to weigh about 18kg of 45-60°C water for injection, glycerol is slowly added under stirring, and the proparacaine hydrochloride raw material is added after stirring until completely dissolved. The proparacaine hydrochloride concentrated solution is added to the preparation tank, and after adding, the standby cooling water for injection is taken to rinse the container twice, and the rinse water is added to the preparation tank and stirred for 5 minutes to make it uniform. Take an appropriate amount of liquid from the preparation tank to measure the pH value. If the pH value of the liquid is not between 5 and 5.7, adjust the pH value of the liquid to 5-5.7 with 0.1mol / L hydrochloric acid solution. Add water for injection to the preparation tank to a full amount of 60.35kg, turn on stirring, and stir for 5 minutes to make it uniform.
[0029] S2 filtration: The drug solution is transported to the first filter for cyclic filtration. After the cyclic filtration, the drug solution is filtered through the second filter and the third filter in sequence. After the filtration, the drug solution is stored in a buffer tank;
[0030] Specifically, after stirring for the specified time in step S1, stop stirring, turn on the material delivery pump, and make the drug liquid circulate through the 0.45μm first filter for 10 minutes, and then take the intermediate product sample for testing at the sampling port after the 0.45μm filter. After the test is qualified, switch the valve to filter the drug liquid through the 0.45μm second filter and the 0.22μm third filter into the buffer tank. After the intermediate product sample is tested and qualified, the drug liquid in the buffer tank is delivered to the filling room.
[0031] S3 filling: discharge the liquid medicine to flush the filling pipeline, adjust the filling machine parameters to convey the liquid medicine for filling, and take out the filled medicine bottles at intervals during the filling process to measure, check and record;
[0032] Specifically, before filling, the filling machine is subjected to a filter element integrity test, the filter elements including a supporting air filter element, a buffer tank compressed air filter element and an A-class air shower device filter element. The pore sizes of the supporting air filter element and the buffer tank compressed air filter element are 0.22 μm, and the pore size of the A-class air shower device filter element is 0.2 μm. The integrity test includes testing the minimum bubble point, water intrusion test pressure, maximum flow value and diffusion flow test pressure. The parameter standards for each filter element test are as follows: the minimum bubble point of support gas filtration is 1000mbar, the water intrusion test pressure is 2500mbar, and the maximum flow value is 0.75ml / min; the minimum bubble point of buffer tank compressed air filtration is 1100mbar, the water intrusion test pressure is 2500mbar, the maximum flow value is 0.38ml / min, and the diffusion flow test pressure is 80Kpa; the minimum bubble point of buffer tank compressed air filtration is 1100mbar, the water intrusion test pressure is 2600mbar, the maximum flow value is 0.75ml / min, and the diffusion flow test pressure is 970mbaar.
[0033] The filling machine is sterilized with high-temperature steam at a temperature of 121°C for 20 minutes. After sterilization, compressed air is introduced into the filling machine for drying, and the drying time is at least 60 minutes. After drying, the liquid medicine is discharged to flush the entire filling pipeline, and the number of discharges cannot be less than 140 times. Then the filling specifications are set, and the dosage of each is 0.430g-0.490g. After the production starts, the first filling plate is taken to check the filling volume. After that, 5 bottles with high liquid levels and 5 bottles with low liquid levels are taken from one plate every hour, and their filling volumes are measured. After the filling volume is qualified, continue filling. It should be noted that the 321M three-in-one blowing, filling and sealing machine of Rommelag, Germany, is used in this embodiment. When the machine runs every 4 hours, the machine operation status needs to be checked, including the following parameters: liquid oil pressure (≤100bar) and temperature (40-65°C), process cooling water temperature (10-18°C) and pressure (4-6bar), extruder plastic particle melting temperature (175-185°C), extruder speed (30-40rpm) and current (30-40A), compressed air total pressure (6.6-10.0bar), buffer tank pressure (≤5bar), support air pressure (≤2bar), liquid sterilizing filter pressure (≤2.5bar).
[0034] S4 Inspection: Inspect the filled medicine bottles one by one, and package and store them after passing the inspection.
[0035] Specifically, the filled medicine bottles are manually inspected by light, and the inspection items include filling volume, sealing, visible foreign matter and appearance. After the light inspection, the products that pass the inspection are leak-checked, coded and labeled one by one, and packaged according to the product batch number and production date, and then scanned and stored in the warehouse.
[0036] This embodiment also provides polyethylene eye drops, which are prepared according to the above production process, wherein the content of proparacaine hydrochloride is 0.5%, the content of glycerol is 0.38%, and the remaining component is water for injection.
[0037] Example 2
[0038] The difference between this embodiment and embodiment 1 is that the content of proparacaine hydrochloride and the content of thickener are different, and the thickener is methylcellulose. Specifically: first weigh the corresponding mass fraction of proparacaine hydrochloride and thickener, and the thickener used in this embodiment is methylcellulose. In this embodiment, 150,000 metering portions are weighed, wherein 450g of proparacaine hydrochloride and 2414g of methylcellulose are weighed. Subsequently, a clean stainless steel barrel is used to weigh about 18kg of 45-60°C injection water, glycerol is slowly added under stirring, and glycerol is stirred until completely dissolved before adding the proparacaine hydrochloride raw material. The proparacaine hydrochloride concentrated solution is added to the dispensing tank, and after adding, the standby cooling injection water is taken to rinse the container twice, and the rinse water is added to the dispensing tank and stirred for 5 minutes to make it uniform. Take an appropriate amount of liquid from the dispensing tank to measure the pH value. If the pH value of the liquid is not between 5 and 5.7, adjust the pH value of the liquid to 5-5.7 with 0.1mol / L hydrochloric acid solution. Add water for injection to the liquid preparation tank to a total of 60.35 kg, turn on stirring, and stir for 5 minutes to make it uniform.
[0039] S2 filtration: The drug solution is transported to the first filter for cyclic filtration. After the cyclic filtration, the drug solution is filtered through the second filter and the third filter in sequence. After the filtration, the drug solution is stored in a buffer tank;
[0040] Specifically, after stirring for the specified time in step S1, stop stirring, turn on the material delivery pump, and make the drug liquid circulate through the 0.45μm first filter for 10 minutes, and then take the intermediate product sample for testing at the sampling port after the 0.45μm filter. After the test is qualified, switch the valve to filter the drug liquid through the 0.45μm second filter and the 0.22μm third filter into the buffer tank. After the intermediate product sample is tested and qualified, the drug liquid in the buffer tank is delivered to the filling room.
[0041] S3 filling: discharge the liquid medicine to flush the filling pipeline, adjust the filling machine parameters to convey the liquid medicine for filling, and take out the filled medicine bottles at intervals during the filling process to measure, check and record;
[0042] Specifically, before filling, the filling machine is subjected to a filter element integrity test, the filter elements including a supporting air filter element, a buffer tank compressed air filter element and an A-class air shower device filter element. The pore sizes of the supporting air filter element and the buffer tank compressed air filter element are 0.22 μm, and the pore size of the A-class air shower device filter element is 0.2 μm. The integrity test includes testing the minimum bubble point, water intrusion test pressure, maximum flow value and diffusion flow test pressure. The parameter standards for each filter element test are as follows: the minimum bubble point of support gas filtration is 1000mbar, the water intrusion test pressure is 2500mbar, and the maximum flow value is 0.75ml / min; the minimum bubble point of buffer tank compressed air filtration is 1100mbar, the water intrusion test pressure is 2500mbar, the maximum flow value is 0.38ml / min, and the diffusion flow test pressure is 80Kpa; the minimum bubble point of buffer tank compressed air filtration is 1100mbar, the water intrusion test pressure is 2600mbar, the maximum flow value is 0.75ml / min, and the diffusion flow test pressure is 970mbaar.
[0043] The filling machine is sterilized with high-temperature steam at a temperature of 121°C for 20 minutes. After sterilization, compressed air is introduced into the filling machine for drying, and the drying time is at least 60 minutes. After drying, the liquid medicine is discharged to flush the entire filling pipeline, and the number of discharges cannot be less than 140 times. Then the filling specifications are set, and the dosage of each is 0.430g-0.490g. After the production starts, the first filling plate is taken to check the filling volume. After that, 5 bottles with high liquid levels and 5 bottles with low liquid levels are taken from one plate every hour, and their filling volumes are measured. After the filling volume is qualified, continue filling. It should be noted that the 321M three-in-one blowing, filling and sealing machine of Rommelag, Germany, is used in this embodiment. When the machine runs every 4 hours, the machine operation status needs to be checked, including the following parameters: liquid oil pressure (≤100bar) and temperature (40-65°C), process cooling water temperature (10-18°C) and pressure (4-6bar), extruder plastic particle melting temperature (175-185°C), extruder speed (30-40rpm) and current (30-40A), compressed air total pressure (6.6-10.0bar), buffer tank pressure (≤5bar), support air pressure (≤2bar), liquid sterilizing filter pressure (≤2.5bar).
[0044] The filled medicine bottles are manually inspected by light, and the inspection items include filling volume, sealing, visible foreign matter and appearance. After the light inspection, the products that pass the inspection are leak-checked, coded and labeled one by one, and packaged according to the product batch number and production date, and then scanned and stored in the warehouse.
[0045] This embodiment also provides polyethylene eye drops, which are prepared according to the above production process, wherein the content of proparacaine hydrochloride is 0.5%, the content of glycerol is 0.38%, and the remaining component is water for injection.
[0046] Example 3
[0047] The difference between this embodiment and embodiment 1 is that the added amounts of proparacaine hydrochloride and the viscosity enhancer in step S1 are different. Specifically, the added mass of proparacaine hydrochloride is 600 g, and the added mass of glycerol is 2110 g. The other preparation steps are consistent with those in embodiment 1.
[0048] The basic parameters of the eye drops prepared in the above examples were tested, and the results were as follows:
[0049] Table 1: Example & Comparative Example Experimental Results
[0050]
[0051] Experimental results analysis:
[0052] The eye drops prepared in the embodiments of the present invention have good viscosity and osmotic pressure, wherein the viscosity value is 3.7 MPa·s, and can drip by gently squeezing during use. At the same time, the osmotic pressure ratio is maintained near 1, which is similar to the osmotic pressure of human tears, and will not cause a sense of oppression in the eyeball during use.
[0053] Experimental Example 1: Multiple-dose eye irritation test
[0054] Experimental samples:
[0055] Test products: samples of Example 1, Example 2 and Example 3 of the present invention
[0056] Reference substance: Marketed product (Hubei Yuanda Tiantianming Pharmaceutical Co., Ltd.)
[0057] Blank control: 0.9% saline
[0058] Experimental method: Three healthy animals of both sexes were selected for each experiment. They were fixed with rabbit clamps, and the test, control and blank control were dripped into the conjunctival sac of the eye, and then the eyelids were gently closed for 10 seconds. The drug was administered twice a day (8:30 and 16:30) for 7 days, and the physiological reactions of the rabbit eyes were observed and recorded before the drug administration and within 1, 6, 24, 48 and 72 hours after the last drug administration.
[0059] Scoring criteria: Draize's scoring criteria were used to determine whether the preparation in this study was irritating. The scoring criteria and eye irritation evaluation criteria were as follows:
[0060] (1) No corneal opacity, scored as 0 points; scattered or diffuse corneal opacity, with clear iris, scored as 1 point; corneal translucent area is easy to distinguish, with blurred iris, scored as 2 points; grayish white translucent area appears on the cornea, with unclear iris details and barely discernible pupil size, scored as 3 points; corneal opacity, with unrecognizable iris, scored as 4 points;
[0061] (2) Normal iris, scored as 0 points; iris folds that are significantly deepened, hyperemia, swelling, mild hyperemia around the cornea, and pupil still reacts to light, scored as 1 point; iris hemorrhage, visible necrosis, no reaction to light (or one of the reactions), scored as 2 points;
[0062] (3) Conjunctival congestion (referring to the palpebral conjunctiva and bulbar conjunctiva) with normal blood vessels, bright red blood vessels, bright red blood vessels with difficult-to-distinguish blood vessels, and diffuse purplish-red blood vessels were scored as 0, 1, 2, and 3 points respectively; no conjunctival edema, slight edema (including eyelids), obvious edema with partial ectropion of the eyelids, edema to the point of nearly half closure of the eyelids, and edema to more than half closure were scored as 0, 1, 2, 3, and 4 points respectively; no conjunctival secretions, a small amount of secretions, secretions that make the eyelids and eyelashes moist or sticky, and secretions that make the entire eye area moist or sticky were scored as 0, 1, 2, and 3 points respectively.
[0063] The comprehensive average score of eye irritation is 0-3 points for no irritation, 4-8 points for mild irritation, 9-12 points for moderate irritation, and 13-16 points for strong irritation. The test results are shown in Table 2 below:
[0064] Table 2: Results of multiple-dose eye irritation test
[0065]
[0066]
[0067] It is obvious to those skilled in the art that the present invention is not limited to the details of the exemplary embodiments described above, and that the present invention can be implemented in other specific forms without departing from the spirit or essential features of the present invention. Therefore, the embodiments should be regarded as exemplary and non-restrictive from any point of view. In addition, it should be understood that although this specification is described in accordance with the embodiments, it does not contain only one technical solution. This narrative of the specification is only for the sake of clarity. Those skilled in the art should regard the specification as a whole, and the technical solutions in the embodiments can also be appropriately combined to form other embodiments that can be understood by those skilled in the art.
Claims
1. A production process of proparacaine hydrochloride eye drops, characterized in that: The following steps are involved: S1: Measure 30% to 40% of the total volume of water for injection, add a viscosity enhancer thereto, the viscosity enhancer is glycerol or methylcellulose, stir and dissolve, add proparacaine hydrochloride thereto, the added mass of proparacaine hydrochloride and viscosity enhancer is 0.5% to 1% and 3.5% to 4% of the total weight respectively, stir until completely dissolved, adjust the pH value with dilute hydrochloric acid, the concentration of dilute hydrochloric acid is 0.1 mol / L, inject the remaining water for injection thereto, stir and mix evenly to prepare a liquid medicine; S2 filtration: The drug solution is transported to the first filter for cyclic filtration. After the cyclic filtration, the drug solution is filtered through the second filter and the third filter in sequence. After the filtration, the drug solution is stored in a buffer tank; S3 filling: discharge the liquid medicine to flush the filling pipeline, adjust the filling machine parameters to convey the liquid medicine for filling. The filling machine is a three-in-one blowing, filling and sealing machine. During the filling process, the filled medicine bottles are taken out at intervals for measurement, inspection and record; S4 Inspection: Inspect the filled medicine bottles one by one, and package and store them after passing the inspection.
2. The production process of proparacaine hydrochloride eye drops according to claim 1, characterized in that: In step S1, the temperature of the water for injection for preparing proparacaine hydrochloride is 45-60° C., and the pH value of the liquid medicine is 5-5.
7.
3. The production process of proparacaine hydrochloride eye drops according to claim 1, characterized in that: In step S2, the filter element size of the first filter is 0.45 μm, and the circulating filtration time is 10 to 15 minutes; the filter element size of the second filter is 0.45 μm; The filter element size of the third filter is 0.22 μm.
4. A production process of proparacaine hydrochloride eye drops according to claim 1, characterized in that: In the step S3, the times of flushing and discharging the medicinal liquid are 140 to 200 times; and the single filling weight is 0.430 g to 0.490 g.
5. The production process of the proparacaine hydrochloride eye drops according to claim 1, characterized in that: In step S3, a filter integrity test is required before the filling machine is used. The filter includes a supporting air filter, a buffer tank compressed air filter and a Class A air shower filter. The pore size of the supporting air filter and the buffer tank compressed air filter is 0.22 μm, and the pore size of the Class A air shower filter is 0.2 μm.
6. A production process of proparacaine hydrochloride eye drops according to claim 5, characterized in that: The filling machine filter element integrity test parameters in step S3 include minimum bubble point, water intrusion test pressure value, maximum flow value and diffusion flow test pressure; The minimum bubble point of the support gas filtration is 1000mbar, the water intrusion test pressure value is 2500mbar, and the maximum flow value is 0.75ml / min; The minimum bubble point of the buffer tank compressed air filtration is 1100mbar, the water intrusion test pressure is 2500mbar, the maximum flow rate is 0.38ml / min, and the diffusion flow test pressure is 80Kpa; The minimum bubble point of the buffer tank compressed air filtration is 1100mbar, the water intrusion test pressure value is 2600mbar, the maximum flow value is 0.75ml / min, and the diffusion flow test pressure is 970mbaar.
7. A production process of proparacaine hydrochloride eye drops according to claim 1, characterized in that: In step S3, the filling machine needs to be sterilized before use, and the sterilization temperature is 121° C. to 135° C. and the time is 20 to 30 minutes.
8. The production process of proparacaine hydrochloride eye drops according to claim 1, characterized in that: The proparacaine hydrochloride eye drops are composed of the following weight fractions: 0.5% to 1% proparacaine hydrochloride, 3.5% to 4% viscosity enhancer, 0.001% to 0.005% hydrochloric acid, and the rest is water for injection.
9. A process for producing proparacaine hydrochloride eye drops according to claim 8, characterized in that: The proparacaine hydrochloride eye drops have an osmotic pressure ratio of 0.93 to 1.08 and a viscosity of 3.7 to 4.2 mPa▪s.
